Quick Answer
Sunshine Biopharma Inc. reported Operating Income Loss of -$5.81 million for the year ending 2024.
- Sunshine Biopharma Inc. showed a decrease of -21.5% in Operating Income Loss from 2023 to 2024.
- This data is from Sunshine Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2025.
- XBRL data for this metric is available from 2011 to 2024 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: -$376.4 thousand | Q1 2013: -$922.9 thousand | Q2 2013: -$152.6 thousand | Q3 2013: -$177.7 thousand | Q1 2014: -$405.9 thousand | Q2 2014: -$765.5 thousand | Q3 2014: -$277.4 thousand | Q1 2015: -$124.8 thousand | Q2 2015: -$368.2 thousand | Q3 2015: -$113.1 thousand | Q1 2016: -$69.7 thousand | Q2 2016: -$471.3 thousand | Q3 2016: -$116.0 thousand | Q1 2017: -$109.0 thousand | Q2 2017: -$472.2 thousand | Q3 2017: -$113.8 thousand | Q1 2018: -$166.7 thousand | Q2 2018: -$580.5 thousand | Q3 2018: -$288.8 thousand | Q1 2019: -$122.2 thousand | Q2 2019: -$66.2 thousand | Q3 2019: -$202.6 thousand | Q1 2020: -$37.7 thousand | Q2 2020: -$128.6 thousand | Q3 2020: -$67.3 thousand | Q1 2021: -$1.28 million | Q2 2021: -$388.6 thousand | Q3 2021: -$496.3 thousand | Q1 2022: -$1.22 million | Q2 2022: -$695.8 thousand | Q3 2022: -$1.72 million | Q1 2023: -$1.83 million | Q2 2023: -$1.01 million | Q3 2023: -$779.5 thousand | Q1 2024: -$1.35 million | Q2 2024: -$1.27 million | Q3 2024: -$1.11 million | Q1 2025: -$1.30 million | Q2 2025: -$2.05 million | Q3 2025: -$1.09 million.
- Over the full 14 years of available data (2011 to 2024), Sunshine Biopharma Inc.'s Operating Income Loss has declined by 945.0%.
- Historical annual values: Fiscal year 2024: -$5.81 million | Fiscal year 2023: -$4.79 million | Fiscal year 2022: -$27.00 million | Fiscal year 2021: -$2.44 million | Fiscal year 2020: -$576.9 thousand | Fiscal year 2019: -$641.6 thousand | Fiscal year 2018: -$1.16 million | Fiscal year 2017: -$857.2 thousand | Fiscal year 2016: -$993.1 thousand | Fiscal year 2015: -$780.3 thousand | Fiscal year 2014: -$1.76 million | Fiscal year 2013: -$1.94 million | Fiscal year 2012: -$706.7 thousand | Fiscal year 2011: -$556.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: